Program Description
In collaboration with the National Association of Specialty Pharmacy.
Generalized myasthenia gravis (gMG) is a chronic, immune-mediated disorder of the neuromuscular junction that causes fluctuating muscle weakness and fatigue across ocular, bulbar, limb, and respiratory muscle groups, often limiting patients’ daily functioning and quality of life. Variability in antibody profiles and disease severity adds specific challenges to gMG management. Even with foundational therapies, many patients continue to experience incomplete symptom control or unpredictable exacerbations. A deeper understanding of the immunologic drivers of gMG has since contributed to the development of targeted biologics, including FcRn blockers and complement inhibitors, that interrupt key disease pathways. As these potentially more individualized treatment strategies reshape the standard of care, specialty pharmacists will be increasingly involved in decisions to guide therapy selection, anticipate safety concerns, and support the monitoring and counseling patients need throughout treatment. This webinar provides specialty pharmacists with a comprehensive overview of gMG pathophysiology and standards of care. The mechanisms and clinical data behind the evolving treatment landscape will be presented, with key insights to help pharmacists translate this knowledge into practical guidance that supports multidisciplinary collaboration and treatment monitoring for patients with gMG.
Target audience: Specialty Pharmacists
Type of activity: Application
Release date: October 29, 2026
Expiration date: October 29, 2027
Learner level: Intermediate, Foundational
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the pathophysiology, clinical manifestations, and current management approaches for generalized myasthenia gravis (gMG), including standards of care and therapeutic gaps
- Explain the mechanisms of action of approved and emerging targeted therapies for gMG and their place in the evolving treatment landscape
- Explore multidisciplinary care for patients with gMG, considering common adverse events, key monitoring needs, and clear patient education about therapy use and expectations
Erica Marini, PharmD, MS, BCPS
Clinical Pharmacist, Neurology
University of Utah Health
Salt Lake City, UT
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This application-based activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-26-339-H01-P. The activity is available for CE credit through October 29, 2027.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Faculty
The following contributors have no relevant financial relationships with ineligible companies to disclose:
Erica Marini, PharmD, MS, BCPS
The staff of Pharmacy Times Continuing Education™ have no relevant financial relationships with ineligible companies.
Any relevant financial relationships listed for these individuals have been mitigated.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
AI Disclosure
Artificial intelligence (AI) tools may have been used to support the development of this continuing education activity, such as for data organization or slide design. All AI-assisted content was reviewed and verified by qualified staff, faculty, or planners before release to ensure accuracy, balance, and freedom from commercial bias. Where applicable, specific details regarding the AI tool, its purpose, and the review process are disclosed within the activity materials. The accredited provider retains full responsibility for the activity’s content, accuracy, balance, and independence.
Educational Disclaimer
Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact: [email protected]
Privacy Policy and Terms of Use Information: www.pharmacytimes.org/terms
